DAYANG BIOTECH issued a preliminary increase, expecting the net profit attributable to the parent company for the first three quarters to be between 74 million yuan and 90 million yuan, a year-on-year increase of 44.35% to 75.56%
DAYANG BIOTECH expects the net profit attributable to the parent company for the first three quarters of 2025 to be between 74 million yuan and 90 million yuan, a year-on-year increase of 44.35% to 75.56%. The net profit after deducting non-recurring gains and losses is expected to be between 67 million yuan and 82 million yuan, a year-on-year increase of 39.04% to 70.17%. The growth in performance is mainly driven by market demand, with sales and prices of the main products, potassium carbonate and veterinary raw materials, rising, leading to an increase in gross profit margin
According to the Zhitong Finance APP, DAYANG BIOTECH (003017.SZ) disclosed its performance forecast for the first three quarters of 2025. The company expects a net profit attributable to shareholders of the listed company to be between 74 million yuan and 90 million yuan, representing a year-on-year increase of 44.35% to 75.56%; the net profit after deducting non-recurring gains and losses is expected to be between 67 million yuan and 82 million yuan, a year-on-year increase of 39.04% to 70.17%.
During the reporting period, the net profit attributable to shareholders of the listed company increased by 44.35% to 75.56% compared to the same period last year, mainly due to market influences that drove the demand for the main products, potassium carbonate and veterinary raw materials. Compared to the same period last year, both sales and prices increased, leading to a rise in gross profit margin
